Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface
of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor …

Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of hematological
malignancies. Compared to our knowledge of B-cell tumors, our understanding of T-cell …

Several clinical studies demonstrate that there exist other immune checkpoints
overexpressed in some PD-1 inhibitor-resistant tumor patients. Among them, Lymphocyte …

The human T-lymphotropic virus type 1 (HTLV-1) retrovirus infects 10–20 million people
globally, with endemic regions in southwestern Japan, the Caribbean basin, Africa, and …

Immune checkpoints (ICPs) can promote tumor growth and prevent immunity‐induced
cancer cell apoptosis. Fortunately, targeting ICPs, such as programmed cell death 1 (PD‐1) …

Current therapies for T-cell acute leukemia are based on risk stratification and have greatly
improved the survival rate for patients, but mortality rates remain high owing to relapsed …

Background: Immune checkpoint inhibitor therapy has demonstrated impressive clinical
benefits in multiple tumor types. TQB2450, a novel monoclonal antibody targeting …

Objective T-cell acute lymphoblastic leukemia (T-ALL) is a rare hematological malignancy
with a poor prognosis. The present study aims to identify the precise risk grouping of …

Human T lymphotropic virus type 1 (HTLV‐1) infection can cause adult T‐cell lymphoblastic
leukemia (ATLL), an incurable, chemotherapy‐resistant malignancy. In a quest for new …

Revisiting PD-1 to target leukaemic stem cells | Nature Cell Biology Skip to main content Thank
you for visiting nature.com. You are using a browser version with limited support for CSS. To …